Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan
Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan Herantis Pharma PlcCompany release 12 June 2017 at 9:00 am Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc's ("Herantis") first-in-human clinical study of the company's investigational product CDNF for the treatment of Parkinson's disease. The company announced earlier this year having secured approvals for the same clinical study in Sweden. The first study site to start patient recruitment will be the Karolinska University Hospital in